Researchers in the Scleroderma Program work collaboratively across specialties to conduct studies in a broad range of areas related to scleroderma. The goal of all our research is to gain a better understanding of scleroderma and its complications, in order to discover and develop better, personalized treatment options that will slow, stop, or reverse the progression of this disease, and ultimately to find a cure.
Basic & Translational Research
In the laboratory, numerous projects of direct relevance to enhancing our understanding of scleroderma are taking place, including studying the mechanisms of blood vessel injury, lung fibrosis, and alternations in the immune system and inflammatory cells in tissue injury.
Our program conducts a multitude of trials that involve testing a type of intervention, such as a potential drug, medical device, activity, or procedure, in people and observing its effects over a period of time. Our trials focus on evaluating the efficacy, safety, and tolerability of potential treatments for scleroderma and its related complications.
Observational studies are done to observe a patient’s disease, symptoms, and health over time without introducing an intervention, such as a medication. Our program has multiple observational studies, including studying the pathogen of scleroderma, and individuals’ experiences of symptoms and the impact they have on daily life.
In addition, our program has created various clinical registries where data (such as biological, clinical, and self-reported) and/or samples are collected at specific points over time to evaluate symptoms of scleroderma and complications associated with the disease.
Learn More About Our Research
Support Our Work
Our scientists are looking for answers on all fronts. We are studying the mechanisms of blood vessel injury, the biology of lung scarring, immune system and inflammatory cells as mediators of tissue injury, and much more. We also are conducting nearly three dozen clinical trials - testing medications, identifying biomarkers for complications of the disease, and understanding pain and depression. Moreover, we are exploring the ways in which scleroderma accelerates the aging process and leads to frailty and mortality.
The Michigan Medicine Scleroderma Program is committed to leading the way in treatment, in research, and in training the physicians and scientists who will continue to push this fight forward. With your support, we can accelerate health care toward a better future.
To make a gift to support our research, please visit the Scleroderma Cure Fund.